Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -870.12% is 121% below its 5-year average of -392.91%, near the high end of its 5-year range (-3351.89%–-38.52%).
43.26% above its 12-month average of -1533.40%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -113.20%.
EBITDA MARGIN
-870.12%
EBITDA MARGIN AVG TTM
-1533.40%
EBITDA MARGIN AVG 3Y
-597.32%
EBITDA MARGIN AVG 5Y
-392.91%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+43.26%
CURRENT VS 3Y AVG
-45.67%
CURRENT VS 5Y AVG
-121.46%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kymera Therapeutics, Inc.
Market Cap
$8.68B
EBITDA Margin
-870.12%
TTM Avg
-1533.40%
3Y Avg
-597.32%
5Y Avg
-392.91%
Market Cap
$8.82B
EBITDA Margin
14.74%
TTM Avg
-8194.33%
3Y Avg
-4134.44%
5Y Avg
-2789.78%
Market Cap
$8.39B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
Market Cap
$8.98B
EBITDA Margin
-340.97%
TTM Avg
-141.29%
3Y Avg
-228.68%
5Y Avg
-264.44%
Market Cap
$9.02B
EBITDA Margin
-25.09%
TTM Avg
-47.89%
3Y Avg
-132.36%
5Y Avg
-132.36%
Market Cap
$9.05B
EBITDA Margin
13.28%
TTM Avg
13.13%
3Y Avg
16.37%
5Y Avg
17.13%
Market Cap
$8.05B
EBITDA Margin
8.34%
TTM Avg
-21.08%
3Y Avg
-58.51%
5Y Avg
-29.82%
Market Cap
$9.34B
EBITDA Margin
13.28%
TTM Avg
13.13%
3Y Avg
16.37%
5Y Avg
17.13%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.68B | -870.12% | -1533.40% | -597.32% | -392.91% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.82B | 14.74% | -8194.33% | -4134.44% | -2789.78% |
| Oscar Health, Inc. (OSCR)vs › | $8.39B | -3.14% | -1.08% | -5.02% | -19.32% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.98B | -340.97% | -141.29% | -228.68% | -264.44% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.02B | -25.09% | -47.89% | -132.36% | -132.36% |
| Bruker Corporation (BRKRP)vs › | $9.05B | 13.28% | 13.13% | 16.37% | 17.13% |
| Caris Life Sciences, Inc. (CAI)vs › | $8.05B | 8.34% | -21.08% | -58.51% | -29.82% |
| Bruker Corporation (BRKR)vs › | $9.34B | 13.28% | 13.13% | 16.37% | 17.13% |
| Insulet Corp. (PODD)vs › | $9.41B | 21.67% | 20.24% | 16.36% | 15.66% |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.84B | -2336.10% | -3741.43% | -3741.43% | -3741.43% |
Gross Margin
102.0%
EBITDA Margin
-870.1%
Operating Margin
-891.3%
Net Margin
-285.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -113.20% |
| 2026-03-31 | -239.00% |
| 2025-12-31 | -3351.89% |
| 2025-09-30 | -3244.28% |
| 2025-06-30 | -718.66% |
| 2025-03-31 | -327.50% |
| 2024-12-31 | -1065.30% |
| 2024-09-30 | -1874.82% |
| 2024-06-30 | -190.98% |
| 2024-03-31 | -547.97% |
| 2023-12-31 | -38.52% |
| 2023-09-30 | -1197.31% |
| 2023-06-30 | -257.27% |
| 2023-03-31 | -469.32% |
| 2022-12-31 | -234.29% |
| 2022-09-30 | -461.89% |
| 2022-06-30 | -348.32% |
| 2022-03-31 | -376.70% |
| 2021-12-31 | -218.04% |
| 2021-09-30 | -137.52% |
| 2021-06-30 | -130.56% |
| 2021-03-31 | -67.82% |
| 2020-12-31 | -96.09% |
| 2020-09-30 | -52.25% |
| 2020-06-30 | -419.80% |
| 2020-03-31 | -316.80% |
| 2019-12-31 | -623.13% |
| 2019-09-30 | -1231.89% |
